FindTrial
Sign In

Bepirovirsen

DRUG10 trials

Sponsors

GlaxoSmithKline, National University Health System, Singapore

Conditions

Chronic Hepatitis BChronic Hepatitis B Virus InfectionHEPATITIS B CHRONICHepatitis BHepatitis B Chronic InfectionHepatitis B, Chronic

Phase 1

Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection
TerminatedNCT05330455
GlaxoSmithKlineHepatitis B
Start: 2022-04-14End: 2026-04-08Updated: 2026-06-16
A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants
CompletedNCT06058390
GlaxoSmithKlineHepatitis B
Start: 2023-10-04End: 2024-05-03Updated: 2025-07-18
Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers
CompletedNCT06422767
GlaxoSmithKlineHepatitis B
Start: 2024-07-18End: 2025-04-28Updated: 2026-07-10
A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease
Active, not recruitingNCT07168356
GlaxoSmithKlineHepatitis B
Start: 2025-09-26End: 2026-08-18Updated: 2026-05-22

Phase 2

Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
Active, not recruitingNCT04954859
GlaxoSmithKlineHepatitis B
Start: 2021-12-14End: 2029-01-24Target: 360Updated: 2026-06-24
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
Active, not recruitingNCT06497504
GlaxoSmithKlineHepatitis B
Start: 2024-09-17End: 2027-04-22Updated: 2026-07-08
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
Active, not recruitingNCT06537414
GlaxoSmithKlineChronic Hepatitis B Virus Infection, Hepatitis B
Start: 2024-11-11End: 2030-05-17Updated: 2026-07-07
Bepirovirsen Liver Biopsy Study
Not yet recruitingNCT07696520
National University Health System, SingaporeHEPATITIS B CHRONIC, Hepatitis B Chronic Infection
Start: 2026-07-01End: 2028-04-30Target: 30Updated: 2026-07-10

Phase 3

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)
CompletedNCT05630807
GlaxoSmithKlineChronic Hepatitis B, Hepatitis B, Chronic
Start: 2022-12-07End: 2026-04-15Updated: 2026-07-08
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)
CompletedNCT05630820
GlaxoSmithKlineChronic Hepatitis B, Hepatitis B, Chronic
Start: 2022-12-06End: 2026-04-13Updated: 2026-07-08

Related Papers

Bepirovirsen induces innate immune proteins independent of HBV.
2026-08-04
Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection.
2026-05-28
A Phase 1, Randomized, Open-Label, Parallel Group Study to Evaluate the Relative Bioavailability and Safety of Subcutaneous Bepirovirsen when Delivered from a Vial or Prefilled Syringe Fitted with a Safety Syringe Device in Healthy Adult Participants.
2025-10-14
Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report
Zeitschrift für Gastroenterologie2024-01-011 citations
B-Clear Phase 2b Study Design: Establishing the Efficacy and Safety of Bepirovirsen in Patients with Chronic Hepatitis B Virus Infection
Advances in Therapy2023-07-012 citations